Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Kidswell Bio Corporation. A complete text table follows the diagram.
The company generated ¥3.28bn while R&D and inventory management consumed cash.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Reported healthcare sales | 1 | 3.3B | 100.0% of reported total |
| Biotech and healthcare products | 2 | 3.3B | Reported six-month total · ¥3.3B |
| Operating profit | 3 | 215M | 6.6% operating margin |
| Operating costs & expenses | 3 | 3.1B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 87.3M | Reported pretax result |
| Kidswell Bio is funding healthcare development while managing inventory | 4 | 128M | Sales reached ¥3.28bn, with ¥388.4m of R&D expense and ¥1.45bn of negative operating cash flow. |
| Net profit attributable to owners | 5 | 60.6M | Reported parent-company result |
| Tax, attribution & other | 5 | 26.7M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Reported healthcare sales | Biotech and healthcare products | 3.3B |
| Biotech and healthcare products | Operating profit | 215M |
| Biotech and healthcare products | Operating costs & expenses | 3.1B |
| Operating profit | Profit before tax | 87.3M |
| Operating profit | Kidswell Bio is funding healthcare development while managing inventory | 128M |
| Profit before tax | Net profit attributable to owners | 60.6M |
| Profit before tax | Tax, attribution & other | 26.7M |